Dapagliflozin vs Ipilimumab

Dapagliflozin vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Dapagliflozin and Ipilimumab.

Mechanism of Action

Dapagliflozin: Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Dapagliflozin — 12.9 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Dapagliflozin — C21H25ClO6.

Molecular Weight: Dapagliflozin — 408.8730 g/mol.

Type: Dapagliflozin — Small molecule; Ipilimumab — Antibody.